Log in

Relevant bibliographies by topics / BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography / Journal articles

To see the other types of publications on this topic, follow the link: BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography.

Journal articles on the topic 'BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography'

Author: Grafiati

Published: 5 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 journal articles for your research on the topic 'BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yozgat, Zübeyir. "Optical Coherence Tomography-Guided Early Versus Late Switching to Dexamethasone Implants in Macular Edema Related to Central Retinal Vein Occlusion: Real-World Evidence." Diagnostics 15, no. 4 (2025): 439. https://doi.org/10.3390/diagnostics15040439.

Full text

Abstract:

Background/Objectives: This study evaluated the outcomes of early versus late switching from intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy to dexamethasone (DEX) implants in patients with macular edema secondary to central retinal vein occlusion (CRVO). The critical role of optical coherence tomography (OCT) in guiding therapeutic decisions and monitoring treatment responses is emphasized. Methods: In this real-world, retrospective study, 61 treatment-naïve CRVO patients were divided into two groups: Group 1 (early switch after three anti-VEGF injections) and Group 2

APA, Harvard, Vancouver, ISO, and other styles

2

Liang, I.-Chia, Hsin-Ching Shen, Yun-Hsiang Chang, and Shu-I. Pao. "The Responses of Different Types of Diabetic Macular Edema after Three Loading Doses of Anti-vascular Growth Factor: Outcomes in Two Medical Centers." Journal of Medical Sciences 44, no. 3 (2024): 119–24. http://dx.doi.org/10.4103/jmedsci.jmedsci_187_23.

Full text

Abstract:

Background: Diabetic macular edema (DME) is currently treated by anti-vascular endothelial growth factor (anti-VEGF). Aim: The aim of this study was to evaluate the effect of intravitreal anti-VEGF in different types of DME classified by optical coherence tomography (OCT). Methods: This retrospective study included 161 treatment-naive eyes (116 patients) diagnosed with DME in two tertiary medical centers, which were classified into three groups according to initial OCT finding: diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD). All eyes received

APA, Harvard, Vancouver, ISO, and other styles

3

Okudan, Süleyman, Sule Acar Duyan, Abdullah Erdem, Ayse Bozkurt Oflaz, and Banu Turgut Ozturk. "Optical Coherence Tomography Biomarkers Predict the Long-Term Restorative Effect of Early Anti-VEGF Treatment on Diabetic Macular Edema." Life 15, no. 2 (2025): 269. https://doi.org/10.3390/life15020269.

Full text

Abstract:

Background/Purpose: This study compared the effects of three induction doses of anti-vascular endothelial growth factor (anti-VEGF) on diabetic macular edema (DME) with that of long-term treatment using biomarkers to find out the predictability potential of early response to anti-VEGF treatment for the long-term restorative effect. Methods: We retrospectively reviewed the clinical and optical coherence tomography (OCT) data of 71 DME eyes treated with three monthly anti-VEGF doses and followed for 1 year. BCVA, central subfield thickness (CST), subretinal fluid (SRF), intraretinal cysts, hyper

APA, Harvard, Vancouver, ISO, and other styles

4

Gu, Zheyao, Xiangying Luo, Ruizhu Sun, Ting Xi, and Chunyuan Zhang. "Long-term effects of the COVID-19 lockdown on the structural and functional outcomes of neovascular AMD patients in Suzhou, China." PLOS ONE 20, no. 3 (2025): e0319677. https://doi.org/10.1371/journal.pone.0319677.

Full text

Abstract:

Background Timely anti-vascular endothelial growth factor (VEGF) therapy is essential for visual function in neovascular age-related macular degeneration (nAMD). The coronavirus pandemic has led to unprecedented delays in anti-VEGF intravitreal therapy because of the need to reduce hospital attendance. Objectives To assess the long-term impact of COVID-19 pandemic-related delays in intravitreal anti-VEGF therapy on nAMD patients. Methods This was a retrospective study of 98 patients (102 eyes) with nAMD whose anti-VEGF treatments were interrupted for > 8 weeks due to the COVID-19 pandemic.

APA, Harvard, Vancouver, ISO, and other styles

5

Tang, Li, Yue Zhao, Ting-Ting Yang, and Jin Yao. "Optical coherence tomography angiography for macular microvessels in ischemic branch retinal vein occlusion treated with conbercept: predictive factors for the prognosis." International Journal of Ophthalmology 16, no. 12 (2023): 2049–55. http://dx.doi.org/10.18240/ijo.2023.12.18.

Full text

Abstract:

AIM: To evaluate the predicative factors of visual prognosis using optical coherence tomography angiography (OCTA) in ischemic branch retinal vein occlusion (BRVO) patients with macular edema (ME) after anti-vascular endothelial growth factor (VEGF) treatment. METHODS: In this retrospective analysis, data from 60 patients (60 eyes) with a definite diagnosis of ischemic BRVO with ME by fundus fluorescein angiography (FFA) were studied. The eyes with ME according to spectral domain optical coherence tomography (SD-OCT) underwent intravitreal conbercept (IVC) and 3+pro re nata (PRN) regimen. The

APA, Harvard, Vancouver, ISO, and other styles

6

Hafner, Michael, Tina R. Herold, Alexander Kufner, et al. "Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes." Journal of Clinical Medicine 14, no. 7 (2025): 2454. https://doi.org/10.3390/jcm14072454.

Full text

Abstract:

Background/Objectives: Macular edema (ME), due to retinal vein occlusion (RVO), is a major cause of vision impairment. Many patients experience suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, necessitating alternative treatment approaches. Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2 (Ang-2), introduces a novel dual-mechanism therapy. This study evaluates the short-term real-world efficacy of switching to Faricimab in patients with treatment-resistant ME secondary to RVO. Methods: This retrospective study included patients from L

APA, Harvard, Vancouver, ISO, and other styles

7

Ramzi Amin and Oliffa Salma Atthahiroh. "Successful Management of Central-Involving Diabetic Macular Edema with Sequential Anti-VEGF Injections in Moderate NPDR: A Case Study." Archives of The Medicine and Case Reports 5, no. 2 (2024): 691–704. https://doi.org/10.37275/amcr.v5i2.741.

Full text

Abstract:

Diabetic macular edema (DME), particularly central-involving DME (CI-DME), represents a primary cause of significant vision impairment among individuals afflicted with diabetic retinopathy (DR). The progression from non-proliferative diabetic retinopathy (NPDR) stages can be complicated by the development of CI-DME, which mandates prompt and effective intervention to preserve visual function. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have emerged as the definitive first-line therapeutic strategy for CI-DME, demonstrating considerable efficacy in reducing macular t

APA, Harvard, Vancouver, ISO, and other styles

8

Dr. Ahmad Hassan, Dr. Aleem Hamza Bajwa, and Dr. Muhammad Kashif Bilal. "<b>EVALUATION OF VISUAL AND ANATOMICAL OUTCOMES AFTER INTRA-VITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION IN PATIENTS WITH DIABETIC DIFFUSE MACULAR EDEMA</b>." Journal of Medical & Health Sciences Review 2, no. 3 (2025). https://doi.org/10.62019/p8r0dq65.

Full text

Abstract:

Aim: This study aimed to evaluate the visual and anatomical outcomes following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in patients with diffuse diabetic macular edema (DME). The primary objective was to assess improvement in best-corrected visual acuity (BCVA) and reduction in central retinal thickness (CRT) as measured by spectral domain optical coherence tomography (OCT). Methods: A descriptive cross-sectional study was conducted at the Ophthalmology Department of Bahawal Victoria Hospital, Bahawalpur, over a six-month period. A total of 147 treatment-naïv

APA, Harvard, Vancouver, ISO, and other styles

9

Dr. Ahmad Hassan, Dr. Aleem Hamza Bajwa, and Dr. Muhammad Kashif Bilal. "<b>EVALUATION OF VISUAL AND ANATOMICAL OUTCOMES AFTER INTRA-VITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION IN PATIENTS WITH DIABETIC DIFFUSE MACULAR EDEMA</b><sup></sup>." Journal of Medical & Health Sciences Review 2, no. 3 (2025). https://doi.org/10.62019/x5z56a52.

Full text

Abstract:

Aim: This study aimed to evaluate the visual and anatomical outcomes following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in patients with diffuse diabetic macular edema (DME). The primary objective was to assess improvement in best-corrected visual acuity (BCVA) and reduction in central retinal thickness (CRT) as measured by spectral domain optical coherence tomography (OCT). Methods: A descriptive cross-sectional study was conducted at the Ophthalmology Department of Bahawal Victoria Hospital, Bahawalpur, over a six-month period. A total of 147 treatment-naïv

APA, Harvard, Vancouver, ISO, and other styles

10

Veiga Reis, Francyne, Pedro Dalgalarrondo, José Edisio da Silva Tavares Neto, Murilo Wendeborn Rodrigues, Ingrid U. Scott, and Rodrigo Jorge. "Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study." International Journal of Retina and Vitreous 9, no. 1 (2023). http://dx.doi.org/10.1186/s40942-023-00449-w.

Full text

Abstract:

Abstract Purpose The aim of this study is to investigate the safety of combined intravitreal injection of dexamethasone aqueous-solution (IVD) and bevacizumab (IVB) in patients with refractory diabetic macular edema (DME) and its effect on intraocular pressure (IOP), best-corrected visual acuity (BCVA) and central subfield thickness (CSFT). Methods This prospective study included 10 patients (10 eyes) with DME refractory to laser photocoagulation and/or anti-vascular endothelial growth factor (anti-VEGF) therapy. A complete ophthalmological examination was performed at baseline, during the fir

APA, Harvard, Vancouver, ISO, and other styles

11

Jitendra, Kumar (M.S.), Kumari Rashmi, and Gupta Archie. "COMPARISION OF VISUAL OUTCOME IN PATIENTS WITH CLINICALLY SIGNIFICANT MACULAR OEDEMAAFTER TREATMENT WITH INTRAVITREAL ANTI -VEGF AND LASER PHOTOCOAGULATION." August 18, 2022. https://doi.org/10.5281/zenodo.7056915.

Full text

Abstract:

<strong>Purpose:</strong> to evaluate, compare and disscuss the therapeutic efficacy of intravitreal anti- VEGF and laser photocoagulation in treatment of CSME. <strong>Material &Method:</strong>We have been selected 100 eyes of 50 patients of diabetic retinopathy with diabetic macular edema (CSME) ,out of which 26 eyes were excluded due to retinal detachment, neovascular glaucoma, complicated cataract, corneal opacity. Total 74 eyes of 37 patients has been selected for the study and divided into two groups with equal numbers of eyes. <strong>Results:</strong> In group 1 patients

APA, Harvard, Vancouver, ISO, and other styles

12

Hein, Martin, Aleksandar Vukmirovic, Ian J. Constable, et al. "Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema." Scientific Reports 13, no. 1 (2023). http://dx.doi.org/10.1038/s41598-023-35286-2.

Full text

Abstract:

AbstractThis prospective single-center study aims to identify biomarkers that predict improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 6 months, in 76 eyes with diabetic macular edema (DME) treated monthly with intravitreal aflibercept. At baseline, all patients underwent standardized imaging with color photography, optical coherence tomography (OCT), fluorescein angiography (FA) and OCT angiography (OCTA). Glycosylated hemoglobin, renal function, dyslipidemia, hypertension, cardiovascular disease and smoking were recorded. Retinal images were graded in

APA, Harvard, Vancouver, ISO, and other styles

13

Moreno, Jazmín Baca, David Berrones Medina, María Fernanda Rosellón-Escobar, and José Gerardo García-Aguirre. "Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema." BMC Ophthalmology 24, no. 1 (2024). http://dx.doi.org/10.1186/s12886-024-03341-9.

Full text

Abstract:

Abstract Purpose To evaluate the short-term effects (hours-days) of intravitreal dexamethasone implant (IDI) in eyes with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) injections. Methods This was a prospective, single-arm, interventional clinical series. Eyes with DME and 3–9 injections of ranibizumab without a good response were included. Patients underwent a single IDI. Best-corrected visual acuity (BCVA) measurement, complete ophthalmic evaluation, and spectral-domain optical coherence tomography (SD-OCT) were performed at baseline, 2 h, 3 h, 24

APA, Harvard, Vancouver, ISO, and other styles

14

Hsieh, Tsung-Cheng, Guang-Hong Deng, Yung-Ching Chang, Fang-Ling Chang, and Ming-Shan He. "A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment." Frontiers in Endocrinology 14 (May 17, 2023). http://dx.doi.org/10.3389/fendo.2023.1108097.

Full text

Abstract:

BackgroundEarly Identifying and characterizing patients with diabetic macular edema (DME) is essential for individualized treatment and outcome optimization. This study aimed to timely investigate optical coherence tomography (OCT) biomarkers of DME refractory to intravitreal anti-vascular endothelial growth factor (VEGF) therapy.MethodsWe retrospective reviewed 72 eyes from 44 treatment-naïve patients who were treated with intravitreal anti-VEGF for DME. OCT scans prior to anti-VEGF were evaluated for serous retinal detachment (SRD), size of outer nuclear layer cystoid changes, diffuse retina

APA, Harvard, Vancouver, ISO, and other styles

15

Liang, Xuemei, Shaozhao Luo, Zhigao Liu, et al. "Unsupervised machine learning analysis of optical coherence tomography radiomics features for predicting treatment outcomes in diabetic macular edema." Scientific Reports 15, no. 1 (2025). https://doi.org/10.1038/s41598-025-96988-3.

Full text

Abstract:

Abstract This study aimed to identify distinct clusters of diabetic macular edema (DME) patients with differential anti-vascular endothelial growth factor (VEGF) treatment outcomes using an unsupervised machine learning (ML) approach based on radiomic features extracted from pre-treatment optical coherence tomography (OCT) images. Retrospective data from 234 eyes with DME treated with three anti-VEGF therapies between January 2020 and March 2024 were collected from two clinical centers. Radiomic analysis was conducted on pre-treatment OCT images. Following principal component analysis (PCA) fo

APA, Harvard, Vancouver, ISO, and other styles

16

El Sayegh, Ahmed. "Studying the Effect of Different Treatment Modalities on Color Vision in Patients with diabetic Macular Edema." SJMS, March 7, 2025, 47–53. https://doi.org/10.55675/sjms.v4i2.127.

Full text

Abstract:

Background: Diabetic macular edema [DME] is a significant contributor to vision loss globally, arising as a part of diabetic retinopathy [DR], which is the most prevalent ocular issue associated with diabetes mellitus [DM]. Aim: This study aimed to evaluate changes in color vision in patients with diabetic macular edema using Roth 28 hue color test before and after using of different modalities of treatment, either macular laser treatment or the intravitreal injection of anti- vascular endothelial growth factor [Anti-VEGF]. Patients and Methods: In a randomized cross-sectional study done on 30

APA, Harvard, Vancouver, ISO, and other styles

17

Tang, Wenyi, Wei Liu, Jingli Guo, et al. "Wide-field swept-source OCT angiography of the periarterial capillary-free zone before and after anti-VEGF therapy for branch retinal vein occlusion." Eye and Vision 9, no. 1 (2022). http://dx.doi.org/10.1186/s40662-022-00297-z.

Full text

Abstract:

Abstract Background The aim of the study was to investigate the changes in the periarterial capillary-free zone (paCFZ) after anti-vascular endothelial growth factor (VEGF) therapy in patients with branch retinal vein occlusion (BRVO) by wide-field swept-source optical coherence tomography angiography (SS-OCTA) and assess their associations with clinical outcomes. Methods In this retrospective observational study of 54 treatment-naïve BRVO patients with macular edema, we reviewed the findings of 12 × 12 mm2 SS-OCTA at baseline, 3, 6, and 12 months after intravitreal ranibizumab injections. The

APA, Harvard, Vancouver, ISO, and other styles

18

Sarkar, Avik Dey, Sanjay Kumar Daulat Thakur, Rupam Roy, and Ajoy Dey Sarkar. "Comparison of Long-term Efficacy of Intravitreal Ranibizumab in Diabetic Retinopathy following Monthly vs Pro Re Nata vs Treat and Extend Protocol." JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022. http://dx.doi.org/10.7860/jcdr/2022/52668.16288.

Full text

Abstract:

Introduction: Diabetic Retinopathy (DR) is a major complication of Diabetes Mellitus (DM), which remains a leading cause of visual loss in working age populations. The most common cause of vision loss in patients with DR is Diabetic Macular Oedema (DME). Intravitreal administration of anti-Anti-Vascular Endothelial Growth Factor (anti-VEGF) agents is currently the mainstay of therapy for both early and advanced stages of DR. Aim: To compare long-term change in Central Macular Thickness (CMT) and Best Corrected Visual Acuity (BCVA) in patients with Non Proliferative Diabetic Retinopathy (NPDR)

APA, Harvard, Vancouver, ISO, and other styles

19

Sarkar, Avik Dey, Sanjay Kumar Daulat Thakur, Rupam Roy, and Ajoy Dey Sarkar. "Comparison of Long-term Efficacy of Intravitreal Ranibizumab in Diabetic Retinopathy following Monthly vs Pro Re Nata vs Treat and Extend Protocol." JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022. http://dx.doi.org/10.7860/jcdr/2022/52668.16288.

Full text

Abstract:

Introduction: Diabetic Retinopathy (DR) is a major complication of Diabetes Mellitus (DM), which remains a leading cause of visual loss in working age populations. The most common cause of vision loss in patients with DR is Diabetic Macular Oedema (DME). Intravitreal administration of anti-Anti-Vascular Endothelial Growth Factor (anti-VEGF) agents is currently the mainstay of therapy for both early and advanced stages of DR. Aim: To compare long-term change in Central Macular Thickness (CMT) and Best Corrected Visual Acuity (BCVA) in patients with Non Proliferative Diabetic Retinopathy (NPDR)

APA, Harvard, Vancouver, ISO, and other styles

20

Turski, Christopher A., Mitchell A. Jacobs, Michelle M. Abou-Jaoude, et al. "Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab." International Journal of Retina and Vitreous 8, no. 1 (2022). http://dx.doi.org/10.1186/s40942-022-00430-z.

Full text

Abstract:

Abstract Background A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving DME (ciDME) at 4–6 weeks and compares treatment responders and non-responders based on spectral domain optical coherence tomography (SD-OCT) features. Methods IRB approved observational, retrospective chart review of patients with ciDME, identified by ICD-10 code, who received IVB and underwent base

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!